Echo Street Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

Echo Street Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-12,563	Closed	-$240K	–	676
2021 Q4	$240K	Sell	12,563 -14,388	-53%	-$317K	﹤0.01%	546
2021 Q3	$665K	Buy	+26,951	New	+$635K	﹤0.01%	343
2021 Q2	–	Sell	-10,351	Closed	-$328K	–	658
2021 Q1	$328K	Buy	+10,351	New	+$429K	﹤0.01%	404

Other funds holding IOVA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Echo Street Capital Management's IOVA Position: Q1 2022 in Review

Echo Street Capital Management sold out of Iovance Biotherapeutics (IOVA) in Q1 2022, closing a stake of 12,563 shares — an estimated $240K sold.

Echo Street Capital Management first reported a position in IOVA in Q1 2021 and held it in 3 quarters. The position peaked at $665K in Q3 2021. 250 funds tracked by Wall St. Rank hold IOVA as of Q1 2022.

Echo Street Capital Management reported no remaining Iovance Biotherapeutics position as of Q1 2022 after selling out during the quarter.
Echo Street Capital Management sold 12,563 Iovance Biotherapeutics shares in Q1 2022, an estimated $240K.
Echo Street Capital Management first reported a position in Iovance Biotherapeutics in Q1 2021 and held it in 3 quarters.
Echo Street Capital Management's Iovance Biotherapeutics position peaked at $665K in Q3 2021.
250 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2022.

Based on Echo Street Capital Management's 13F filing for Q1 2022, filed 16 May 2022.